Key Takeaway: Precision BioSciences has announced the opening of its first clinical trial site in the U.S. for the ELIMINATE-B trial, which focuses on chronic hepatitis B patients. The trial, designated as Phase 1 for PBGENE-HBV, is actively recruiting participants at Massachusetts General Hospital and is set to report additional data from higher dose cohorts in 2025.
Price reaction · baseline $5.67 (2025-10-06 close) · hit pre-market · 1 other DTIL headline(s) in the window, move may be shared
day 0 close
+0.2%
Market Sentiment Analysis
POSITIVE FACTORS
First clinical trial site opened in the U.S.
Active recruitment of chronic hepatitis B patients.
Progressing on track for additional data in 2025.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Massachusetts General Hospital , Harvard Medical School , actively recruiting chronic hepatitis B patients along with multiple global clinical trial sites – – Phase 1 ELIMINATE-B trial for PBGENE-HBV is progressing and on track to report additional data from higher dose cohorts in 2025 – DURHAM,
Frequently Asked Questions
What is the ELIMINATE-B trial?
The ELIMINATE-B trial is a Phase 1 clinical trial for PBGENE-HBV targeting chronic hepatitis B.
Where is the first clinical trial site located?
The first clinical trial site for the ELIMINATE-B trial is at Massachusetts General Hospital.
When will additional data from the trial be reported?
Additional data from higher dose cohorts of the trial is expected to be reported in 2025.
Who is recruiting for the trial?
Massachusetts General Hospital, affiliated with Harvard Medical School, is actively recruiting patients.